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Dr Jack A. Roth (Houston, Texas). Recent advances with 3-di-
mensional conformal techniques can compensate for lung motion,
and they can allow delivery of very high single fractions to primary
lung tumors in patients with clinical stage I lung cancer. The mem-
bers of the Pittsburgh group are innovators in applying novel technol-
ogies to the treatment of thoracic cancers, and now they demonstrate
the application of this technology to the treatment of lung cancer in
patients with medically inoperable disease. Importantly, thoracic sur-
geons evaluated all patients and performed treatment planning in col-
laboration with radiation oncologists. As these novel technologies
evolve, it is going to be critical for thoracic surgeons to continue to
participate in the delivery of SRS and other new therapies.
There have been several series of patients with clinical stage I
lung cancer treated with stereotactic radiation in the United States
and Japan, and these include both medically inoperable and surgi-
cally resectable disease. Both the local control rates and the 5-year
survivals in those studies appear to be comparable to those reported
in surgical series. These studies administered considerably higher
doses of radiation than used in this study, which could explain
the high local failure rate that Pennathur and colleagues observed.
There are planned or completed phase II clinical trials, both in
the United States under the Radiation Therapy Oncology Group
and in Japan under the Japan Clinical Oncology Group, to evaluate
SRS for the treatment of resectable stage I NSCLC. If these results
are confirmed, this type of technology could be competitive with
surgery for operable stage I disease, and I think that it is therefore
imperative that we begin to consider the design of randomized clin-
ical trials to eventually assess the benefit of SRS.
I have several questions. Dr Pennathur, one fraction of 20 Gy,
which has a biologic effective dose calculated by our radiation on-
cologists as 60 Gy, is less than the conventional dose of 66 Gy in 33
fractions that’s usually given to these patients. This could explain
the high local recurrence rate. Why was such a low dose given,
and are there plans to increase both the dose and the margins be-
yond those that you reported in your study?
Second, the patients had multiple comorbidities. Could you es-
timate the lung cancer–specific survival for your cohort of patients?
Finally, do the radiation oncologists at your institution plan to
offer this technology at higher doses to patients with potentially op-
erable disease?602 The Journal of Thoracic and Cardiovascular SurDr Pennathur. Thank you, Dr Roth, for your comments and ques-
tions. I’m going to take the third question first. No, our radiation on-
cologists are not going to offer SRS to patients with operable stage I
NSCLC. We believe that the data is in evolution and although the data
from Japan is interesting, do not yet support that. I will discuss further
about this after addressing the first two questions.
In answer to your first question, yes, I think that the local recur-
rence rate in our series has been high. It’s about 40% of local pro-
gression. I think several factors may have played a role in this. As
you rightly pointed out, I think dose is the number one factor. A 20-
Gy dose has been estimated to be equivalent to anywhere between
60 Gy and 70 Gy and is estimated by the linear quadratic equation,
which makes a lot of assumptions, so that the radiation oncologist
who actually calculates it comes with a specific number. Everybody
agrees that this is not very precise, but our estimate is that it’s some-
where around 70 Gy or so. The second issue is that with higher
doses, the three-fraction schema of 20 Gy times 3, a 60 Gy dose,
is supposed to be equal to a biologic effective dose of 180 Gy.
Now, Timmerman and colleagues13 have shown that with central
lesions, this regimen has been highly toxic. The mortality from us-
ing this regimen has been close to 10%, which is somewhat alarm-
ing, but most of these patients who died had central tumors. Of the 6
deaths they had, 4 were of patients with central tumor. In our series
of 21 patients, 11 had central tumors and 10 had peripheral tumors.
Early on, when we started out using SRS, we used the lower dose.
The first reason for this was caution. The second reason was that the
pulmonary function test results in these patients were quite poor,
and the radiation oncologists had some concerns about giving
a high dose. I must add that during the last year and a half, we
have gone up to three fractions of 20 Gy for peripheral lesions.
In this series, 4 patients received a total of 60 Gy for peripheral le-
sions, but the follow-up is not long enough as for the original 20
patients, and almost all the recurrences were in the first 20-Gy
group, so the local progression rate is significant.
In terms of the margins, yes, we shoot for a margin of at least 5
mm, but we presented data about a year ago suggesting that if the
margins were less than 1 cm in wedge resections, our recurrence
rates were much higher. So we want to go for about a 1 cm margin,
but this is limited by the critical structures around the lesion and by
the radiation exposure that these critical structures sustain. Unfor-
tunately, many times it’s not 1 cm. It’s closer to 5 mm.
Finally, I think the issue about recurrence is the technique. Early
on, we used the breath-hold technique. Now we are using more dy-
namic tracking wherein the patient’s breathing is dynamically
tracked by the camera and then the radiation is delivered in sync
with the patient’s breathing. In this series, again, only 5 patients
were treated that way. The rest were treated with the breath-hold
technique. I think that all this may explain the increase in terms
of local progression. Finally, I think the issue is that our aggressive
follow-up and imaging also contributed to early detection of recur-
rence.
Now, the second question was related to the dose, Dr Roth?
Dr Roth. Yes.
Dr Pennathur. With respect to the dose, again, we have gone up
to 60 Gy for peripheral lesions. For central lesions, we are looking
at one of the Japanese regimens, which is 12 Gy times 4, for
a 48-Gy dose, which gives a biologically effective dose of more
than 100 Gy.gery c March 2009
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operable cases, I think that the Japanese literature is quite encourag-
ing. Unfortunately, I think that there is a disconnect between the sur-
vival figures quoted in the Japanese literature and the survival
figures quoted in the United States. I think, for example, some of
the Japanese surgical series have had approximately 90% to 100%
5-year survivals, with survivals in the 80% range quoted after
SRS I think in the United States we have not seen survivals in the
90% range for stage I lung cancer at 5 years. I wonder whether there
is some biologic difference in terms of the patients we are treating,
perhaps in the basic substrate of the patients themselves. I think it
would be reasonable for patients with medically inoperable disease
to compare the CyberKnife with some other therapy for medically
inoperable cases. With respect to SRS for surgically operable cases,
I think that we may need more data in the United States to pursue
this. Certainly, as you mentioned, this is a hotly investigated area,
with a lot of interest from a lot of groups, including ours, and we
are looking at this very closely. Thank you for your comments
and excellent questions.
Dr Tomasz Grodzki (Szczecin, Poland). I congratulate you on
your excellent presentation; however, I am still doubtful whether
those patients really had inoperable disease, because if you evalu-
ated them, you probably performed mediastinoscopy. This means
that they survived anesthesia. If you placed those metal markers,
it means that they were subjected to pneumothorax, and they all sur-
vived it. This was a kind of functional test for segmentectomy. I
think I would prefer to perform segmentectomy and then radiation.
What was the N status of those patients? You didn’t mention it.
Was this clinical stage I or pathologic stage I?
Dr Pennathur. These patients, if they had enlarged lymph nodes
and positive PET scan results in the mediastinum, underwent a me-
diastinoscopy and N2 disease was ruled out. Otherwise, they did
not undergo any other invasive staging, such as video-assisted thor-
acoscopic surgical staging, for example. Two patients underwent
mediastinoscopy, and they certainly did not have any invasive pro-
cedures before SRS. So this is primarily clinical staging, with inva-
sive staging in selected patients, to rule out N2 disease. The issue of
medical inoperability is a critical one, and I think that it is important
that surgeons be involved, because what is medically inoperable for
a thoracic surgeon is not the same as what is medically inoperable
for a pulmonologist and is different still for a radiation oncologist.
These patients had a low FEV1 of 0.6 and had multiple comorbid-
ities. The median Charlson Comorbidity Index value was 5.5, and
we have validated data suggesting that the incidence of postopera-
tive complications is significantly higher on multivariate analysis
once this score reaches 3 to 4. So I do think that this was a high-
risk group of patients. I think, however, that your point is excellent.
There may be patients with predominant upper lobe emphysema
and lung cancer there with low FEV1 who would certainly benefit
from lung resection along with lung volume reduction. I therefore
think that it’s critical for thoracic surgeons to evaluate these patients
before declaring the disease inoperable, and these patients were all
very carefully assessed before they were subjected to SRS.
Dr Jessica S. Donington (Stanford, California). I congratulate
you on this work. At Stanford we also feel that it’s important for
surgeons to embrace this kind of technology. We are really the ex-
perts on the treatment of early-stage lung cancer, and we need to
know all the options that are available for our patients.The Journal of Thoracic and CI have two questions. One has to do with the local recurrences. In
our work, we’ve noticed a difference in local recurrences between
T1 and T2 tumors. The ability to give the full isodose for those
smaller tumors is much easier. Did you note this? Also, one of
the significant differences we find between surgery and radiother-
apy is clearly the treatment of the lymph nodes, and we did have
more nodal recurrences than we would like. That was an area where
there were a lot of recurrences. Can you comment on the difference
between your local recurrences, nodal recurrences, and distant re-
currences in these patients?
Dr Pennathur. We didn’t really find a difference in terms of lo-
cal progression-free survival between T1 and T2 tumors. Nine pa-
tients had local progression. In many instances, this is associated
with regional and also distant disease, but it was counted as local
progression. Local-only progression occurred in fewer than 5 pa-
tients. Sometimes people might report it that way, but for this study
we decided that any local recurrences need to be considered. Thank
you for your comments and questions.
Dr Mark Block (Hollywood, Florida). I enjoyed your presenta-
tion, and I congratulate your group on really providing objective lead-
ership in studying the ablative therapies for these early lung cancers.
I have two questions. First, how do you deal with lesions that are
close to important structures, like hilar lesions close to the pulmo-
nary artery or the aorta, a lingular lesion that’s next to a left ventric-
ular free wall? You don’t want to give them 70 Gy radiation.
Second, are you at all familiar with the new fiducial-free systems
that are being marketed? The reason I have concerns about that is
that in our local market, the person who owns the CyberKnife facil-
ity–because it’s an independent facility–was boasting to me the
other day about how they’re going to get a fiducial-free system
and then be able to take the patient right from the screening CT
scanner to the CyberKnife to zap those little 5-mm lesions without
ever having to worry about a biopsy. This leads me to the last point,
which is that I think the use of this technology is unfortunately go-
ing to be driven more by marketing and promotion than by science.
I think your group is in a unique position to provide the most objec-
tive data on evaluating this technology. Most of the other literature
out there has been written by people with a financial interest in in-
creasing SRS use. I therefore challenge you to think about ways in
which you can influence the debate by more than simply presenting
your objective data. There must be policy discussions about how
we’re going to manage these patients.
Dr Pennathur. Thank you, Dr Block. Those are really excellent
thoughts. In terms of the fiducial-free system, we have heard about
it and we have discussed it with the radiation oncologists and with
the physicists. At this point, we are not going to get into it, because
we don’t have the data to prove that this fiducial less system is as
accurate in tracking the tumor as the one we currently use with
fiducials. Some tumors move about a good 2 or 3 cm with breath-
ing, and whether the fiducial-free system is going to be tracking
this, we really do not know. The issue in terms of the study of these
newer technologies is that I think that thoracic surgeons should take
a lead. We have been taking care of this for a long time, and we also
look at things a little bit differently and more objectively in terms of
recurrence and survival and so forth. I think that it will be critical for
us to get involved with these newer technologies, and we are trying
to evaluate every aspect critically and to identify patients who
would benefit versus patients who might not benefit.ardiovascular Surgery c Volume 137, Number 3 603
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to tolerate a 20-Gy dose, which equals a 70-Gy dose. The moment
you go up to a higher dose, however, you add risk. I think in the
Stanford series, a 25-Gy dose in a central location was associated
with about 2 deaths, for single-fraction radiation. A 20-Gy dose,
however, may be somewhat safer. The Japanese have proposed
a newer schema, which is a total of 48 Gy, with each fraction
only about 12 Gy for central lesions. I think we do have to be a little
careful about the central lesions and what kind of dose we need to
use, and I think we need to follow, evaluate them, and study them
more carefully.
Dr Todd L. Demmy (Buffalo, New York). I have two quick
questions. Your group is also reporting on RFA for similar pa-
tients. How are you sorting out SRS technology versus the
competing technology of RFA? By extension, we’re finding pa-
tients with RFA sometimes don’t have recurrence at the target
lesion but at a location nearby, which points to a problem with
this technology. You can only target what you can see on the
initial CT scan, not the minimal residual disease that you can’t
image and that is presumably cleared better by lobectomy or
segmentectomy. When you report your results, are you going
differentiate the recurrences at the initial target area from604 The Journal of Thoracic and Cardiovascular Surlesions that recurred nearby in the downstream path of the tu-
mor spread?
Dr Pennathur. Thanks for your comments, Dr Demmy. In terms
of the RFA and CyberKnife, I think they can potentially be comple-
mentary. We absolutely don’t use RFA for central lesions. We had 1
patient who underwent RFA and brachytherapy who had a fatal he-
moptysis about 3 weeks after the procedure, and we do not know
whether it was the brachytherapy or RFA which caused it, but we
haven’t used RFA since for any central lesions. We use a modified
dose schema for the central lesions. In terms of peripheral lesions,
they can be complementary. For example, if there is a recurrence af-
ter RFA, one could use SRS, and vice versa. And sometimes for a pe-
ripheral lesion, it is the choice of the physician as to the technology
to use. I think the other point which you brought up, which is that we
treat the small lesion which we see but we don’t look into micro-
scopic spread, is critical. I think the issue about margins becomes
very important, and we believe that we need to have at least a 1-cm
margin. We evaluate our recurrences in the lobe as well as the
progressed lesion, and I think the upcoming American College of
Surgeons Oncology Group (ACOSOG) trial on RFA also is going
to be reporting the same way. We thank the Association for the
privelege of presenting this paper.gery c March 2009
